Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524606

BERLDRG

img img img img
No Data Available

BERYL DRUGS LTD. Share Price Update

As of the latest trading session, BERYL DRUGS LTD. share price is currently at ₹ 22.25, which is up by ₹ 0.88 from its previous closing. Today, the stock has fluctuated between ₹ 21.12 and ₹ 22.50. Over the past year, BERYL DRUGS LTD. has achieved a return of -34.65 %. In the last month alone, the return has been -1.98 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BERYL DRUGS LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    11.30

  • P/E Ratio (TTM)

    48.37

  • Beta

    0.55

  • Book Value / share

    18.62

  • Return on equity

    6.30%

  • EPS (TTM)

    0.46

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.01

info icon alternate text

BERYL DRUGS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 5.12
Operating Expense 4.90
Net Profit 0.01
Net Profit Margin (%) 0.19
Earnings Per Share (EPS) 0.02
EBITDA 0.73
Effective Tax Rate (%) 96.15
Particulars JUN 2025 (Values in Cr)
Revenue 4.79
Operating Expense 4.77
Net Profit 0.02
Net Profit Margin (%) 0.41
Earnings Per Share (EPS) 0.04
EBITDA 0.55
Effective Tax Rate (%) 71.42
Particulars MAR 2025 (Values in Cr)
Revenue 3.97
Operating Expense 5.12
Net Profit 0.15
Net Profit Margin (%) 3.77
Earnings Per Share (EPS) 0.30
EBITDA 0.50
Effective Tax Rate (%) -50.00
Particulars DEC 2024 (Values in Cr)
Revenue 5.31
Operating Expense 5.24
Net Profit 0.05
Net Profit Margin (%) 0.94
Earnings Per Share (EPS) 0.10
EBITDA 0.59
Effective Tax Rate (%) 68.75
Particulars SEP 2024 (Values in Cr)
Revenue 5.61
Operating Expense 5.53
Net Profit 0.01
Net Profit Margin (%) 0.17
Earnings Per Share (EPS) 0.01
EBITDA 0.56
Effective Tax Rate (%) 90.90
Particulars MAR 2025 (Values in Cr)
Revenue 21.15
Operating Expense 21.69
Net Profit 0.58
Net Profit Margin (%) 2.74
Earnings Per Share (EPS) 1.14
EBITDA 2.65
Effective Tax Rate (%) 33.33
Particulars MAR 2024 (Values in Cr)
Revenue 26.73
Operating Expense 26.11
Net Profit 0.77
Net Profit Margin (%) 2.88
Earnings Per Share (EPS) 1.52
EBITDA 2.67
Effective Tax Rate (%) 23.76
Particulars MAR 2023 (Values in Cr)
Revenue 26.89
Operating Expense 26.18
Net Profit 0.77
Net Profit Margin (%) 2.86
Earnings Per Share (EPS) 1.52
EBITDA 2.21
Effective Tax Rate (%) 22.44
Particulars MAR 2022 (Values in Cr)
Revenue 14.60
Operating Expense 15.71
Net Profit -0.66
Net Profit Margin (%) -4.52
Earnings Per Share (EPS) -1.30
EBITDA 0.58
Effective Tax Rate (%) 30.52
Particulars MAR 2021 (Values in Cr)
Revenue 14.09
Operating Expense 14.39
Net Profit 0.24
Net Profit Margin (%) 1.70
Earnings Per Share (EPS) 0.47
EBITDA 2.09
Effective Tax Rate (%) 31.42
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.66
ROE % 6.30
ROCE % 9.93
Total Debt to Total Equity 0.50
EBITDA Margin 12.53
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.52
ROE % 9.07
ROCE % 10.80
Total Debt to Total Equity 0.57
EBITDA Margin 10.03
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.84
ROE % 10.03
ROCE % 11.25
Total Debt to Total Equity 0.64
EBITDA Margin 8.44
Particulars MAR 2022 (Values in Cr)
Book Value / Share 14.32
ROE % -8.67
ROCE % -3.72
Total Debt to Total Equity 0.68
EBITDA Margin 4.11
Particulars MAR 2021 (Values in Cr)
Book Value / Share 15.57
ROE % -1.29
ROCE % 2.79
Total Debt to Total Equity 0.67
EBITDA Margin 11.64
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.81
Total Assets 15.96
Total Liabilities 15.96
Total Equity 9.50
Share Outstanding 5071700
Price to Book Ratio 1.13
Return on Assets (%) 3.62
Return on Capital (%) 4.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 17.48
Total Liabilities 17.48
Total Equity 8.92
Share Outstanding 5071700
Price to Book Ratio 1.67
Return on Assets (%) 4.39
Return on Capital (%) 5.48
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.57
Total Assets 17.51
Total Liabilities 17.51
Total Equity 8.06
Share Outstanding 5071700
Price to Book Ratio 0.77
Return on Assets (%) 4.37
Return on Capital (%) 6.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.27
Total Assets 17.82
Total Liabilities 17.82
Total Equity 7.29
Share Outstanding 5072000
Price to Book Ratio 0.73
Return on Assets (%) -3.69
Return on Capital (%) -5.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.45
Total Assets 18.64
Total Liabilities 18.64
Total Equity 7.92
Share Outstanding 5072000
Price to Book Ratio 0.42
Return on Assets (%) 1.28
Return on Capital (%) 1.84
Particulars MAR 2025 (Values in Cr)
Net Income 0.86
Cash from Operations 2.81
Cash from Investing -0.39
Cash from Financing -1.55
Net change in Cash 0.68
Free Cash Flow 5.00
Particulars MAR 2024 (Values in Cr)
Net Income 1.00
Cash from Operations 1.02
Cash from Investing -1.08
Cash from Financing 0.10
Net change in Cash -0.15
Free Cash Flow 2.37
Particulars MAR 2023 (Values in Cr)
Net Income 0.98
Cash from Operations 2.54
Cash from Investing -1.30
Cash from Financing -1.16
Net change in Cash 0.01
Free Cash Flow 4.10
Particulars MAR 2022 (Values in Cr)
Net Income -0.95
Cash from Operations -0.43
Cash from Investing 0.52
Cash from Financing -0.23
Net change in Cash -0.18
Free Cash Flow -0.02
Particulars MAR 2021 (Values in Cr)
Net Income 0.34
Cash from Operations 0.36
Cash from Investing 0.25
Cash from Financing -0.53
Net change in Cash 0.05
Free Cash Flow 1.41
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.83 13.15 1.39 205.61 25.97 / 53.83
BLISS GVS PHARMA LTD 164.40 15.87 1.53 1739.17 105.05 / 195.85
CIPLA LTD 1434.60 21.30 3.52 115882.86 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 323.90 8.51 2.43 953.27 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2392.95 42.53 23.73 40538.02 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.20 22.11 3.79 208.44 25.97 / 53.83
AMRUTAJAN HEALTH LTD 611.55 31.19 5.16 1768.03 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 8211.55 88.80 25.69 20528.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 162.60 21.94 1.55 1720.13 105.05 / 195.85

BERYL DRUGS LTD. shareholding pattern

Holding

73.61%
26.38%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

BERYL DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
22.25 4.16 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 22.20
  • 26 Days 22.70
  • 10 Days 22.40
  • 50 Days 22.80
  • 12 Days 22.50
  • 100 Days 22.90
  • 20 Days 22.60
  • 200 Days 23.80
21.66 PIVOT

First Support

20.82

First Resistance

22.20

Second Support

20.28

Second Resistance

23.04

Third Support

19.44

Third Resistance

23.58

RSI

47.28

ADX

18.91

MACD

-0.17

Williams % R

-60.76

Commodity Channel Index (CCI)

-108.69

Date

2026-01-14

Week

497.00

Same Day

130.00

Month

5542.00

1 Year

0.57

3 Year

0.44

Over 1 Month

-1.98%

down

Over 1 Year

-34.65%

down

Over 3 Months

-0.31%

down

Over 3 Years

14.12%

down

Over 6 Months

4.85%

down

Over 5 Years

22.06%

down

BERYL DRUGS LTD. Corporate Actions

Top Gainers

BERYL DRUGS LTD. Share Price

Beryl Drugs Limited, based in Indore, was incorporated on August 24, 1993. The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The Shares of Company were listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

The Company thereafter has been engaged in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally. It offers I.V.fluids, and a range of small and large volume injectables. It provides a range of eye/ear drops, veterinary products, and injections. It sells products through sales and distribution network. In addition, it offers research and development, as well as contract manufacturing services. Beryl Drugs Ltd. is based in Indore, India.

Beryl emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. It owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The manufacturing facilities of the Company are in compliance with WHO GMP specifications. The Company is in tune with the current manufacturing trends in healthcare industry. The Company is an ISO 9001:2000 certified for quality management, which acknowledges quality as the first and the foremost important aspect into the business of healthcare products.

Parent organization Indian Private
NSE symbol [-]
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Beryl Drugs Ltd?

Answer Field

Beryl Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 22.25 as on Jan 14 2026 11:04 AM.

What is the Market Cap of Beryl Drugs Ltd Share?

Answer Field

The market cap of Beryl Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 11.30 as on Jan 14 2026 11:04 AM.

What is the 52 Week High and Low of Beryl Drugs Ltd?

Answer Field

The 52 Week High and Low of Beryl Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 43.00 and ₹ 17.35.

What is 1 year return for Beryl Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -34.65%.

What is the P/E Ratio of Beryl Drugs Ltd Share?

Answer Field

As on Jan 14 2026 11:04 AM the price-to-earnings (PE) ratio for Beryl Drugs Ltd share is 48.37.

What is the PB ratio of Beryl Drugs Ltd Share?

Answer Field

As on Jan 14 2026 11:04 AM, the price-to-book (PB) ratio for Beryl Drugs Ltd share is 18.62.

How to Buy Beryl Drugs Ltd Share?

Answer Field

You can trade in Beryl Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beryl Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beryl Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beryl Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59